Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | TACR2 | P21452 | 8/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449020 | 0.93 | FPR2 (0.49) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3449290 | 0.93 | FPR2 (0.49) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3448805 | 0.93 | FPR2 (0.49) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL6015050 | 0.89 | YAP1 (0.45) | CACNA1BYAP1 | |
| SCHEMBL3448717 | 0.87 | FPR2 (0.52) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3449428 | 0.86 | CHRM2 (0.45) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3449415 | 0.85 | CYP51A1 (0.44) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3450219 | 0.83 | CCR1 (0.42) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL3452313 | 0.82 | CCR1 (0.44) | FPR2CHRM2CHRM1CHRM3 | |
| SCHEMBL6015065 | 0.81 | ALDH1A1 (0.43) | FPR2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | FPR2 417/4885CHRM2 855/4885CHRM1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.